Investor Tom Hulick highlights Broadcom's AI-focused, power-efficient ASICs and Eli Lilly's GLP-1 drug pipeline, while StockStory cautions against uncritical acceptance of Wall Street price targets.
Tesla faces declining global sales, safety concerns, and scrutiny over CEO Elon Musk's controversies, as competition intensifies and the Cybertruck struggles with pricing challenges.
Axalta beats Q3 estimates, raises guidance, and secures a strategic BMW deal, signaling confidence in revenue growth despite near-term market caution.
Investor Tom Hulick highlights Broadcom's AI-focused, power-efficient ASICs and Eli Lilly's GLP-1 drug pipeline, while StockStory cautions against uncritical acceptance of Wall Street price targets.
Tesla faces declining global sales, safety concerns, and scrutiny over CEO Elon Musk's controversies, as competition intensifies and the Cybertruck struggles with pricing challenges.
Axalta beats Q3 estimates, raises guidance, and secures a strategic BMW deal, signaling confidence in revenue growth despite near-term market caution.